Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AMLX |
---|---|---|
09:32 ET | 11170 | 3.11 |
09:34 ET | 2056 | 3.1188 |
09:36 ET | 6992 | 3.12 |
09:38 ET | 4000 | 3.14 |
09:39 ET | 6649 | 3.1489 |
09:41 ET | 2142 | 3.1589 |
09:43 ET | 1100 | 3.17 |
09:45 ET | 7400 | 3.15 |
09:48 ET | 710 | 3.13 |
09:50 ET | 13818 | 3.14 |
09:52 ET | 3704 | 3.14 |
09:54 ET | 1658 | 3.1211 |
09:56 ET | 2496 | 3.11 |
09:57 ET | 5800 | 3.1099 |
09:59 ET | 30252 | 3.115 |
10:01 ET | 6068 | 3.13 |
10:03 ET | 1560 | 3.15 |
10:06 ET | 1344 | 3.155 |
10:08 ET | 3411 | 3.175 |
10:10 ET | 1186 | 3.171 |
10:12 ET | 7501 | 3.195 |
10:14 ET | 2100 | 3.185 |
10:15 ET | 59929 | 3.2 |
10:17 ET | 11222 | 3.1845 |
10:19 ET | 9550 | 3.15 |
10:21 ET | 3700 | 3.1536 |
10:24 ET | 3272 | 3.15 |
10:26 ET | 24342 | 3.125 |
10:28 ET | 4935 | 3.125 |
10:30 ET | 1999 | 3.11 |
10:32 ET | 3118 | 3.125 |
10:33 ET | 2554 | 3.13 |
10:35 ET | 210417 | 3.155 |
10:37 ET | 1400 | 3.165 |
10:39 ET | 3186 | 3.16 |
10:42 ET | 2887 | 3.17 |
10:44 ET | 1800 | 3.165 |
10:46 ET | 200 | 3.165 |
10:48 ET | 1700 | 3.165 |
10:50 ET | 9963 | 3.19 |
10:51 ET | 1550 | 3.185 |
10:53 ET | 3525 | 3.185 |
10:55 ET | 2502 | 3.185 |
10:57 ET | 6048 | 3.205 |
11:00 ET | 6798 | 3.2 |
11:02 ET | 1847 | 3.195 |
11:04 ET | 1526 | 3.195 |
11:06 ET | 927 | 3.195 |
11:08 ET | 4400 | 3.195 |
11:09 ET | 1743 | 3.195 |
11:11 ET | 3661 | 3.195 |
11:13 ET | 260 | 3.195 |
11:15 ET | 3500 | 3.195 |
11:18 ET | 29652 | 3.195 |
11:20 ET | 2200 | 3.195 |
11:22 ET | 1000 | 3.195 |
11:24 ET | 14564 | 3.185 |
11:26 ET | 2242 | 3.19 |
11:27 ET | 4701 | 3.175 |
11:29 ET | 2200 | 3.175 |
11:31 ET | 1338 | 3.175 |
11:33 ET | 1412 | 3.16 |
11:36 ET | 1192 | 3.15 |
11:38 ET | 2919 | 3.15 |
11:40 ET | 1864 | 3.155 |
11:42 ET | 2400 | 3.155 |
11:44 ET | 5210 | 3.155 |
11:45 ET | 1064 | 3.155 |
11:47 ET | 3328 | 3.16 |
11:49 ET | 6396 | 3.16 |
11:51 ET | 400 | 3.16 |
11:54 ET | 14227 | 3.168 |
11:56 ET | 1400 | 3.17 |
11:58 ET | 600 | 3.165 |
12:00 ET | 1000 | 3.165 |
12:02 ET | 2326 | 3.165 |
12:03 ET | 7655 | 3.17 |
12:05 ET | 3305 | 3.175 |
12:07 ET | 5546 | 3.18 |
12:09 ET | 1877 | 3.175 |
12:12 ET | 6230 | 3.175 |
12:14 ET | 1614 | 3.175 |
12:16 ET | 2262 | 3.19 |
12:18 ET | 2378 | 3.19 |
12:20 ET | 2096 | 3.185 |
12:21 ET | 720 | 3.185 |
12:23 ET | 500 | 3.185 |
12:25 ET | 600 | 3.185 |
12:27 ET | 1068 | 3.185 |
12:30 ET | 700 | 3.185 |
12:32 ET | 1982 | 3.19 |
12:34 ET | 1372 | 3.1988 |
12:36 ET | 5983 | 3.2 |
12:38 ET | 657 | 3.205 |
12:41 ET | 600 | 3.2001 |
12:43 ET | 9953 | 3.205 |
12:45 ET | 2700 | 3.2001 |
12:48 ET | 1422 | 3.2012 |
12:50 ET | 1579 | 3.205 |
12:52 ET | 984 | 3.205 |
12:54 ET | 3309 | 3.205 |
12:56 ET | 5243 | 3.19 |
12:57 ET | 6614 | 3.195 |
12:59 ET | 3727 | 3.195 |
01:01 ET | 264 | 3.195 |
01:03 ET | 2100 | 3.2 |
01:06 ET | 3281 | 3.2 |
01:08 ET | 4264 | 3.195 |
01:10 ET | 14486 | 3.2 |
01:12 ET | 1100 | 3.2 |
01:14 ET | 1900 | 3.2 |
01:15 ET | 17652 | 3.2 |
01:17 ET | 2615 | 3.195 |
01:19 ET | 1300 | 3.2 |
01:21 ET | 2823 | 3.2 |
01:24 ET | 800 | 3.195 |
01:26 ET | 964 | 3.195 |
01:28 ET | 2395 | 3.195 |
01:30 ET | 1364 | 3.195 |
01:32 ET | 1404 | 3.19 |
01:33 ET | 30345 | 3.215 |
01:35 ET | 14740 | 3.225 |
01:37 ET | 2934 | 3.225 |
01:39 ET | 1122 | 3.225 |
01:42 ET | 800 | 3.225 |
01:44 ET | 1325 | 3.225 |
01:46 ET | 1200 | 3.23 |
01:48 ET | 755 | 3.23 |
01:50 ET | 869 | 3.225 |
01:51 ET | 11065 | 3.25 |
01:53 ET | 7152 | 3.235 |
01:55 ET | 500 | 3.235 |
01:57 ET | 2300 | 3.23 |
02:00 ET | 200 | 3.225 |
02:02 ET | 2228 | 3.23 |
02:04 ET | 2396 | 3.23 |
02:06 ET | 1325 | 3.23 |
02:08 ET | 1403 | 3.22 |
02:09 ET | 3710 | 3.215 |
02:11 ET | 2926 | 3.22 |
02:13 ET | 300 | 3.21 |
02:15 ET | 14383 | 3.2 |
02:18 ET | 1000 | 3.195 |
02:20 ET | 500 | 3.195 |
02:22 ET | 9106 | 3.185 |
02:24 ET | 12456 | 3.2 |
02:26 ET | 1912 | 3.185 |
02:27 ET | 960 | 3.185 |
02:29 ET | 900 | 3.19 |
02:31 ET | 2453 | 3.175 |
02:33 ET | 6469 | 3.18 |
02:36 ET | 5025 | 3.1712 |
02:38 ET | 3491 | 3.185 |
02:40 ET | 700 | 3.185 |
02:42 ET | 700 | 3.185 |
02:44 ET | 13016 | 3.205 |
02:45 ET | 300 | 3.205 |
02:47 ET | 2200 | 3.205 |
02:49 ET | 10295 | 3.22 |
02:51 ET | 7356 | 3.2128 |
02:54 ET | 100 | 3.21 |
02:56 ET | 8620 | 3.21 |
02:58 ET | 3883 | 3.195 |
03:00 ET | 4796 | 3.21 |
03:02 ET | 3124 | 3.195 |
03:03 ET | 20341 | 3.2 |
03:05 ET | 2082 | 3.195 |
03:07 ET | 1300 | 3.2 |
03:09 ET | 156 | 3.205 |
03:12 ET | 1160 | 3.205 |
03:14 ET | 2029 | 3.195 |
03:16 ET | 3700 | 3.195 |
03:18 ET | 2910 | 3.195 |
03:20 ET | 1084 | 3.205 |
03:21 ET | 1970 | 3.2012 |
03:23 ET | 6221 | 3.205 |
03:25 ET | 1800 | 3.205 |
03:27 ET | 800 | 3.205 |
03:30 ET | 42555 | 3.21 |
03:32 ET | 7488 | 3.205 |
03:34 ET | 949 | 3.208 |
03:36 ET | 11521 | 3.2 |
03:38 ET | 10414 | 3.2 |
03:39 ET | 3882 | 3.205 |
03:41 ET | 700 | 3.2 |
03:43 ET | 10861 | 3.195 |
03:45 ET | 8816 | 3.165 |
03:48 ET | 3300 | 3.165 |
03:50 ET | 9323 | 3.185 |
03:52 ET | 8173 | 3.185 |
03:54 ET | 16744 | 3.195 |
03:56 ET | 26410 | 3.195 |
03:57 ET | 20750 | 3.205 |
03:59 ET | 190546 | 3.24 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Amylyx Pharmaceuticals Inc | 220.6M | -1.3x | --- |
Organogenesis Holdings Inc | 379.2M | -22.9x | --- |
Amarin Corporation PLC | 257.6M | -7.6x | --- |
Ironwood Pharmaceuticals Inc | 658.1M | 95.3x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Coherus BioSciences Inc | 119.8M | -2.6x | --- |
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $220.6M |
---|---|
Revenue (TTM) | $298.8M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.45 |
Book Value | $6.40 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.